Oragenics, Inc. Banner Image

Oragenics, Inc.

  • Ticker OGEN
    Exchange NYSE More
  • Industry Biotechnology More
  • Sector Healthcare More
Oragenics, Inc. Logo Image
  • 11-50 Employees
  • Based in Tampa, Florida
Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases, including those caused by coronaviruses and multidrug-resistant organisms. Its lead product is NT-CoV2-1, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The NT-CoV2-1 program leverages coronavirus spike protein research licensed from the NIH and the NRC withMore a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics.
Oragenics, Inc.

Most Recent Annual Report

Oragenics, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Oragenics, Inc. Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!